<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37074774</PMID><DateCompleted><Year>2023</Year><Month>09</Month><Day>05</Day></DateCompleted><DateRevised><Year>2023</Year><Month>10</Month><Day>07</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1533-2500</ISSN><JournalIssue CitedMedium="Internet"><Volume>23</Volume><Issue>7</Issue><PubDate><Year>2023</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Pain practice : the official journal of World Institute of Pain</Title><ISOAbbreviation>Pain Pract</ISOAbbreviation></Journal><ArticleTitle>Management of high-dose intrathecal baclofen pump explant: A case report.</ArticleTitle><Pagination><StartPage>847</StartPage><EndPage>850</EndPage><MedlinePgn>847-850</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/papr.13229</ELocationID><Abstract><AbstractText Label="BACKGROUND">Intrathecal baclofen (ITB) is a proven, effective treatment for refractory spasticity and chronic pain, with applications ranging from spinal cord injury to amyotrophic lateralsclerosis (ALS). Despite its effectiveness, the withdrawal syndrome of intrathecal baclofen can be life-threatening.</AbstractText><AbstractText Label="CASE REPORT">This case describes the treatment of a patient with chronic spasticity related to ALS with an ITB pump infection requiring explant and a prolonged period of antibiotics before reimplantation. A 62-year-old man with ALS-related spasticity maintained on high-dose ITB for 20&#x2009;years presented to the emergency department with one week of fever, confusion, and localized erythema to the R-side of his abdomen. Laboratories indicated a mild leukocytosis 12.9&#x2009;K/uL and imaging showed a 2.9-cm fluid collection with fat stranding surrounding the ITB pump. The pack was explanted, and the patient started on intravenous antibiotics. Due to the high baclofen dosage, our pain service recommended PO (per os) baclofen 30&#x2009;mg every 6&#x2009;h via gastrostomy and PO diazepam 10&#x2009;mg every 6&#x2009;h via gastrostomy. These doses were titrated carefully to avoid oversedation while preventing withdrawal symptoms. On Day 23 postexplant, the patient had the baclofen pump reimplanted and baclofen titrated over three days to his previous dose of ITB.</AbstractText><AbstractText Label="CONCLUSION">This case demonstrates a successful approach to avoiding severe baclofen withdrawal using PO baclofen combined with PO diazepam. The high dose of maintenance ITB (1188.8 mcg/day), the inability to reinsert the patient's intrathecal pump, and the high risk of intubation in a patient with severe neuromuscular dysfunction all made this a challenging case.</AbstractText><CopyrightInformation>&#xa9; 2023 World Institute of Pain.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Belisle Haley</LastName><ForeName>Campbell</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0002-1903-2788</Identifier><AffiliationInfo><Affiliation>Department of Emergency Medicine, University of California, Irvine Medical Center, Orange, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Agrawal</LastName><ForeName>Mrinal</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Division of Pain Medicine, Department of Anesthesiology, University of California, Irvine Medical Center, Orange, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Newton</LastName><ForeName>Keith</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Division of Pain Medicine, Department of Anesthesiology, University of California, Irvine Medical Center, Orange, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yeung</LastName><ForeName>Brent</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Division of Pain Medicine, Department of Anesthesiology, University of California, Irvine Medical Center, Orange, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dayal</LastName><ForeName>Rakhi</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Division of Pain Medicine, Department of Anesthesiology, University of California, Irvine Medical Center, Orange, California, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>04</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Pain Pract</MedlineTA><NlmUniqueID>101130835</NlmUniqueID><ISSNLinking>1530-7085</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>H789N3FKE8</RegistryNumber><NameOfSubstance UI="D001418">Baclofen</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009125">Muscle Relaxants, Central</NameOfSubstance></Chemical><Chemical><RegistryNumber>Q3JTX2Q7TU</RegistryNumber><NameOfSubstance UI="D003975">Diazepam</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001418" MajorTopicYN="N">Baclofen</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009125" MajorTopicYN="Y">Muscle Relaxants, Central</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015918" MajorTopicYN="N">Infusion Pumps, Implantable</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009128" MajorTopicYN="N">Muscle Spasticity</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003975" MajorTopicYN="N">Diazepam</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013375" MajorTopicYN="Y">Substance Withdrawal Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D059350" MajorTopicYN="Y">Chronic Pain</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007278" MajorTopicYN="N">Injections, Spinal</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">baclofen</Keyword><Keyword MajorTopicYN="N">intrathecal</Keyword><Keyword MajorTopicYN="N">pain</Keyword><Keyword MajorTopicYN="N">pump</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>1</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>3</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>9</Month><Day>5</Day><Hour>6</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>4</Month><Day>19</Day><Hour>12</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>4</Month><Day>19</Day><Hour>11</Hour><Minute>53</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37074774</ArticleId><ArticleId IdType="doi">10.1111/papr.13229</ArticleId></ArticleIdList><ReferenceList><Title>REFERENCES</Title><Reference><Citation>Koulousakis A, Kuchta J. Intrathecal antispastic drug application with implantable pumps: results of a 10 year follow-up study. Acta Neurochir Suppl. 2007;97(Pt 1):181-4. https://doi.org/10.1007/978-3-211-33079-1_24. PMID: 17691374.</Citation></Reference><Reference><Citation>Zuniga RE, Perera S, Abram SE. Intrathecal baclofen: a useful agent in the treatment of well-established complex regional pain syndrome. Reg Anesth Pain Med. 2002;27(1):90-3. https://doi.org/10.1053/rapm.2002.29244. PMID: 11799510.</Citation></Reference><Reference><Citation>Loubser PG, Akman NM. Effects of intrathecal baclofen on chronic spinal cord injury pain. J Pain Symptom Manage. 1996;12(4):241-7. https://doi.org/10.1016/0885-3924(96)00152-2. PMID: 8898508.</Citation></Reference><Reference><Citation>McClelland S III, Bethoux FA, Boulis NM, Sutliff MH, Stough DK, Schwetz KM, et al. Intrathecal baclofen for spasticity-related pain in amyotrophic lateral sclerosis: efficacy and factors associated with pain relief. Muscle Nerve. 2008;37(3):396-8. https://doi.org/10.1002/mus.20900. PMID: 17894358.</Citation></Reference><Reference><Citation>Verschueren A, Grapperon AM, Delmont E, Attarian S. Prevalence of spasticity and spasticity-related pain among patients with amyotrophic lateral sclerosis. Rev Neurol (Paris). 2021;177(6):694-8. https://doi.org/10.1016/j.neurol.2020.08.009. Epub 2021 Jan 7. PMID: 33423807.</Citation></Reference><Reference><Citation>Romito JW, Turner ER, Rosener JA, Coldiron L, Udipi A, Nohrn L, et al. Baclofen therapeutics, toxicity, and withdrawal: a narrative review. SAGE Open Med. 2021;9:20503121211022197. https://doi.org/10.1177/20503121211022197. PMID: 34158937; PMCID: PMC8182184.</Citation></Reference><Reference><Citation>Ng L, Khan F, Young CA, Galea M. Symptomatic treatments for amyotrophic lateral sclerosis/motor neuron disease. Cochrane Database Syst Rev. 2017;1(1):CD011776. https://doi.org/10.1002/14651858.CD011776.pub2. PMID: 28072907; PMCID: PMC6469543.</Citation></Reference><Reference><Citation>Borowski A, Littleton AG, Borkhuu B, Presedo A, Shah S, Dabney KW, et al. Complications of intrathecal baclofen pump therapy in pediatric patients. J Pediatr Orthop. 2010;30(1):76-81. https://doi.org/10.1097/BPO.0b013e3181c6b257. PMID: 20032747.</Citation></Reference><Reference><Citation>Saulino M, Anderson DJ, Doble J, Farid R, Gul F, Konrad P, et al. Best practices for intrathecal baclofen therapy: troubleshooting. Neuromodulation. 2016;19(6):632-41.</Citation></Reference><Reference><Citation>Ross JC, Cook AM, Stewart GL, Fahy BG. Acute intrathecal baclofen withdrawal: a brief review of treatment options. Neurocrit Care. 2011;14(1):103-8. https://doi.org/10.1007/s12028-010-9422-6. PMID: 20717751.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>